CELU Celularity Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1752828 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.5%
TTM net income YoY34.7%
TTM EPS YoY43.2%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—
Margins
Gross margin55.1%
Operating margin-105.8%
Net margin-165.2%
FCF margin—
EBITDA margin-90.8%
Returns
ROE-6,367.2%
ROA-57.6%
ROIC (approx.)—
Asset turnover0.35x
Leverage & solvency
Liabilities / assets121.2%
Debt / equity—
Current ratio0.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.03x
Accruals ratio-55.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.43M | $3.85M | $4.10M | $5.28M | $5.74M | $11.43M | $18.13M | $9.30M |
| Cost of revenue | $2.35M | $1.45M | $7.37M | $3.90M | $5.24M | $3.55M | $7.34M | $3.88M |
| Gross profit | $3.08M | $2.39M | -$3.27M | $1.38M | $494,000 | $7.87M | $10.79M | $5.41M |
| R&D expense | $2.03M | $2.99M | $3.35M | $4.60M | $3.35M | $3.73M | $3.83M | $3.92M |
| SG&A expense | $4.94M | $9.16M | $15.06M | $9.31M | $12.63M | $14.26M | $16.06M | $12.65M |
| Operating income | -$4.24M | -$10.13M | -$22.06M | -$12.90M | -$15.86M | -$10.49M | -$9.28M | -$11.53M |
| Interest expense | $177,000 | $352,000 | — | — | $1.94M | $2.44M | — | — |
| Pretax income | $706,000 | $874,000 | -$24.36M | -$23.08M | -$24.52M | -$19.75M | -$13.29M | -$16.10M |
| Income tax | — | — | — | — | — | — | — | $0 |
| Net income | $706,000 | $874,000 | -$24.36M | -$23.08M | -$24.52M | -$19.75M | -$13.29M | -$16.10M |
| EBITDA | -$3.05M | -$8.54M | -$20.25M | -$11.45M | -$14.40M | -$8.65M | -$7.40M | -$10.01M |
| EPS (basic) | 0.02 | 0.02 | — | -0.88 | -1.02 | -0.84 | — | -0.73 |
| EPS (diluted) | 0.02 | 0.02 | — | -0.88 | -1.02 | -0.84 | — | -0.73 |
| Weighted avg. shares (diluted) | 29.34M | 30.30M | — | 26.35M | 24.02M | 23.53M | — | 21.98M |
| Balance sheet | ||||||||
| Cash & equivalents | $586,000 | $368,000 | $6.17M | $120,000 | $10.94M | $10.30M | $10.98M | $10.33M |
| Receivables | $4.68M | $4.78M | $4.65M | — | — | — | — | — |
| Inventory | $718,000 | $477,000 | $571,000 | $2.56M | $4.41M | $6.20M | $5.41M | $3.96M |
| Current assets | $6.45M | $6.30M | $12.32M | $10.60M | $17.26M | $22.08M | $20.56M | $14.50M |
| PP&E, net | $53.38M | $54.57M | $55.80M | $57.22M | $58.67M | $60.13M | $61.60M | $63.21M |
| Goodwill | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M |
| Intangibles | $6.33M | $7.39M | $7.76M | $8.13M | $8.51M | $8.88M | $9.25M | $9.62M |
| Total assets | $96.17M | $99.48M | $107.33M | $114.24M | $120.28M | $128.88M | $132.68M | $128.84M |
| Current liabilities | $59.74M | $70.58M | $80.76M | $65.31M | $69.23M | $58.69M | $53.68M | $76.17M |
| Short-term debt | — | — | — | — | $6.30M | $6.30M | — | $42.61M |
| Long-term debt | — | — | $33.81M | $35.67M | — | — | — | — |
| Total debt | — | — | $33.81M | $35.67M | — | — | — | — |
| Total liabilities | $131.70M | $134.74M | $145.39M | $134.33M | $145.78M | $134.38M | $123.84M | $111.56M |
| Shareholders' equity | -$35.53M | -$35.26M | -$38.06M | -$20.09M | -$25.50M | -$5.51M | $8.84M | $17.28M |
| Net debt | — | — | $27.64M | $35.55M | — | — | — | — |
| Shares outstanding | 29.28M | 29.18M | 28.84M | 28.22M | 24.61M | 23.94M | 22.55M | 21.98M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.11M | $1.45M | -$5.10M | -$4.16M | -$999,000 | -$2.99M | $1.59M | -$144,000 |
| Capital expenditure | — | — | — | — | — | — | $56,000 | $35,000 |
| Free cash flow | — | — | — | — | — | — | $1.54M | -$179,000 |
| Investing cash flow | — | — | — | — | — | — | -$1.56M | -$35,000 |
| Financing cash flow | $1.02M | -$7.34M | $11.22M | $3.48M | $1.63M | $2.32M | $643,000 | -$79,000 |
| Depreciation & amortization | $1.18M | $1.60M | $1.80M | $1.45M | $1.46M | $1.83M | $1.88M | $1.52M |
| Stock-based compensation | $844,000 | $1.24M | $9.85M | $471,000 | $2.45M | $2.64M | $2.94M | $2.67M |
Free plan shows the latest 8 periods; Pro shows all 30 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.